Boston Therapeutics has completed a trial evaluating the dietary supplement Sugardown at the University of Sydney.
Sugardown is intended to help in the reduction of post-meal elevation of blood glucose.
In the trial, Sugardown was evaluated in overweight, healthy adults with a mean body mass index (BMI) value of 27.3kg/m².
Boston president Ken Tassey said the study has important endpoints that support Sugardown's potential as a powerful tool for those who struggle with blood sugar management.
Boston chief technology officer Joan Sellers said the company is in the process of summarising the data to demonstrate the significant reduction in postprandial blood glucose following consumption of Sugardown chewable tablets.